ENHA

Key Facts

• The S-1 registers up to 6,704,973 shares of Class A common stock and up to 6,426,735 shares issuable upon PIPE warrant exercise for resale by selling securityholders.
• The company will not receive any proceeds from the sale of shares by selling securityholders; it may receive proceeds from cash exercise of PIPE warrants.
• As of June 30, 2026, the company had $19.6 million in cash and cash equivalents, an accumulated deficit of $110.4 million, and recorded a net loss of $78.4 million for the six months ended June 30, 2026.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year of the issuance of its June 30, 2026 financial statements.
• The company completed a SPAC business combination on May 7, 2026, and its Class A common stock trades on the NYSE under the symbol ENHA.
• The inaugural 2026 Enhanced Games was held on May 24, 2026, generating more than $32 million in contracted sponsorship value.
• The company completed a $50 million private placement (PIPE) in three tranches, with the final tranche closing on August 14, 2026.
• The PIPE warrants have an exercise price of $3.89 per share, subject to anti-dilution adjustments, and are exercisable for up to 12,853,468 shares of Class A common stock.
• The company identified material weaknesses in internal control over financial reporting related to entity-level controls, third-party valuation reports, and user-access IT general controls.
• The company is a controlled company under NYSE rules, with Apeiron and its affiliates holding more than 50% of voting power.

Financial Impact

The filing itself does not raise capital for the company. The company had $19.6M cash, a $110.4M accumulated deficit, and a $78.4M net loss for H1 2026. The PIPE warrants, if exercised for cash at $3.89/share, could yield up to ~$50M in gross proceeds, but this is contingent on the stock price and warrant terms.

Risk Factors

• Going-concern risk: only $19.6M cash with $78.4M H1 loss, substantial doubt about ability to continue as a going concern.
• Massive dilution risk: up to 12.85M PIPE warrant shares at $3.89, plus 6.7M shares registered for resale, and ~117M locked-up shares subject to staged release.
• Unproven business model: limited revenue, only one inaugural event held, and the concept of permitting performance-enhancing substances faces significant regulatory, reputational, and market acceptance risks.
• Material weaknesses in internal controls over financial reporting, increasing risk of financial misstatement or reporting delays.
• High concentration of voting power with Apeiron (>50%), limiting minority shareholder protections and governance standards.

Market Snapshot

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status